Calamos Advisors’s Myriad Genetics MYGN Stock Holding History

Calamos Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-8,770	Closed	-$255K	–	696
2018 Q4	$255K	Hold	8,770	–	–	﹤0.01%	637
2018 Q3	$403K	Buy	+8,770	New	+$390K	﹤0.01%	621
2015 Q2	–	Sell	-7,200	Closed	-$245K	–	706
2015 Q1	$255K	Buy	+7,200	New	+$258K	﹤0.01%	649

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Calamos Advisors's MYGN Position: Q1 2019 in Review

Calamos Advisors sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 8,770 shares — an estimated $255K sold.

Calamos Advisors first reported a position in MYGN in Q1 2015 and held it in 3 quarters. The position peaked at $403K in Q3 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

Calamos Advisors reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
Calamos Advisors sold 8,770 Myriad Genetics shares in Q1 2019, an estimated $255K.
Calamos Advisors first reported a position in Myriad Genetics in Q1 2015 and held it in 3 quarters.
Calamos Advisors's Myriad Genetics position peaked at $403K in Q3 2018.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Calamos Advisors's 13F filing for Q1 2019, filed 12 Apr 2019.